13.73
Lyell Immunopharma Inc stock is traded at $13.73, with a volume of 255.15K.
It is up +10.55% in the last 24 hours and up +53.58% over the past month.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$12.42
Open:
$12.59
24h Volume:
255.15K
Relative Volume:
1.89
Market Cap:
$203.31M
Revenue:
$54,000
Net Income/Loss:
$-210.26M
P/E Ratio:
-17.38
EPS:
-0.79
Net Cash Flow:
$-159.01M
1W Performance:
+44.68%
1M Performance:
+53.58%
6M Performance:
+12.63%
1Y Performance:
-58.14%
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
LYEL
Lyell Immunopharma Inc
|
13.73 | 230.82M | 54,000 | -210.26M | -159.01M | -0.79 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
Oct-17-22 | Initiated | H.C. Wainwright | Buy |
Jul-12-21 | Initiated | BofA Securities | Buy |
Jul-12-21 | Initiated | Goldman | Buy |
Jul-12-21 | Initiated | JP Morgan | Overweight |
Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
What is the dividend policy of Lyell Immunopharma Inc. stockAchieve rapid portfolio growth with expert guidance - jammulinksnews.com
How to use a screener to detect Lyell Immunopharma Inc. breakouts Free Technical Entry Strategy for Beginners - Newser
What catalysts could drive Lyell Immunopharma Inc. stock higher in 2025Extraordinary profit generation - jammulinksnews.com
How volatile is Lyell Immunopharma Inc. stock compared to the marketInvest confidently with expert support - jammulinksnews.com
Sectors Driving Future Growth for Lyell Immunopharma Inc. StockHigh Potential Safe Trades - Newser
What makes Lyell Immunopharma Inc. stock price move sharplyEarly Breakout Tracker - Newser
What drives Lyell Immunopharma Inc. stock priceExceptional financial outcomes - PrintWeekIndia
Lyell Immunopharma $100M Deal: Can Buyers Hold the Stock After 20% Surge? - FXLeaders
Lyell Immunopharma (LYEL) Stock Soars Following Private Placement Announcement - FinancialBuzz.com
Lyell Immunopharma's $100M Private Placement: How Milestone-Driven Capital Raises De-Risk Biotechs and Create Asymmetric Upside - AInvest
What makes Lyell Immunopharma Inc. stock attractive to long term investorsExplosive capital appreciation - jammulinksnews.com
Lyell Immunopharma announces up to $100M equity private placement - TipRanks
Everest Medicines raises $200M; Epirium Bio targets $55M Series B - Endpoints News
Lyell Immunopharma Taps Investors For $100 Million In New Funding - Finimize
Is Lyell Immunopharma Inc. a good long term investmentBreakthrough profits - PrintWeekIndia
Lyell Immunopharma secures up to $100 million in private placement By Investing.com - Investing.com South Africa
Lyell Immunopharma Secures $100 Million in Private Placement - TipRanks
Why Lyell Immunopharma Inc. stock attracts strong analyst attentionROI Focused Stock Calls - Newser
Lyell Immunopharma Announces up to $100 Million Equity Private Placement - GlobeNewswire
Lyell Immunopharma Raises $100M to Advance Breakthrough Cancer Cell Therapy Through Pivotal Trials - Stock Titan
Is Lyell Immunopharma Inc. stock overhyped or has real potentialOutstanding capital returns - jammulinksnews.com
What analysts say about Lyell Immunopharma Inc. stockMarket-leading capital gains - PrintWeekIndia
Positive week for Lyell Immunopharma, Inc. (NASDAQ:LYEL) institutional investors who lost 70% over the past year - simplywall.st
Lyell Immunopharma Inc. Stock Analysis and ForecastHigh-yield investments - jammulinksnews.com
Lyell Immunopharma's LYL314: A High-Risk, High-Reward Catalyst in the CAR T-Cell Space - AInvest
Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement (LYEL) - Seeking Alpha
Lyell Immunopharma registers 625,000 shares for resale - MSN
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):